MTNB Stock Overview
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Matinas BioPharma Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.29 |
52 Week High | US$0.89 |
52 Week Low | US$0.11 |
Beta | 1.53 |
1 Month Change | 7.77% |
3 Month Change | 27.99% |
1 Year Change | -36.22% |
3 Year Change | -72.39% |
5 Year Change | -73.65% |
Change since IPO | -77.70% |
Recent News & Updates
Shareholder Returns
MTNB | US Biotechs | US Market | |
---|---|---|---|
7D | 0.7% | -0.5% | 0.6% |
1Y | -36.2% | 9.6% | 29.5% |
Return vs Industry: MTNB underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: MTNB underperformed the US Market which returned 29.5% over the past year.
Price Volatility
MTNB volatility | |
---|---|
MTNB Average Weekly Movement | 12.1% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MTNB's share price has been volatile over the past 3 months.
Volatility Over Time: MTNB's weekly volatility has decreased from 48% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 34 | Jerry Jabbour | https://www.matinasbiopharma.com |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Matinas BioPharma Holdings, Inc. Fundamentals Summary
MTNB fundamental statistics | |
---|---|
Market cap | US$62.98m |
Earnings (TTM) | -US$21.26m |
Revenue (TTM) | US$2.16m |
29.2x
P/S Ratio-3.0x
P/E RatioIs MTNB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MTNB income statement (TTM) | |
---|---|
Revenue | US$2.16m |
Cost of Revenue | US$14.69m |
Gross Profit | -US$12.53m |
Other Expenses | US$8.73m |
Earnings | -US$21.26m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.098 |
Gross Margin | -580.45% |
Net Profit Margin | -984.81% |
Debt/Equity Ratio | 0% |
How did MTNB perform over the long term?
See historical performance and comparison